Development of a first-in-class brachyury inhibitor for rare, veteran-relevant cancers

Active Project Grant Awarded

Award ID
HT9425261E386
Recipient
Awarding agency
Obligated
$488,765

Award facts

Assistance listing
12.420 Military Medical Research and Development
Completion date 11% complete
Place of performance
Seattle, WA 98122, USA

Award details come from USAspending.gov.

About this award

The Defense Health Agency awarded Talus Bioscience Inc. $488,765 on August 26, 2026, through Project Grant HT9425261E386 under the Military Medical Research and Development Assistance Listing (CFDA 12.420). The award funds development of a first-in-class Brachyury inhibitor for rare, veteran-relevant cancers. Work is performed in Seattle, Washington 98122, and the ultimate completion date is October 31, 2028. The program's stated purpose is supporting basic, applied, and advanced biomedical research to transform health care for Service Members and the American public.

Quick answers

Who received award HT9425261E386?

HT9425261E386 was awarded to Talus Bioscience Inc. by Defense Health Agency (Department of Defense) on August 26, 2026.

How much is award HT9425261E386 worth?

$488,765 has been obligated on HT9425261E386.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award